The US pharma said results of the latest phase 3 trial showed that REGEN-COV (casirivimab+imdevimab) significantly reduced progression to symptomatic COVID-19 disease in uninfected individuals.

It’s a dictum that has stood him well during his 30-year career as a top executive at Regeneron Pharmaceuticals, which received widespread publicity late last year after former President Donald Trump ...